WO2007092315A3 - Immunostimulation by cpg oligonucleotide-virus complexes - Google Patents

Immunostimulation by cpg oligonucleotide-virus complexes Download PDF

Info

Publication number
WO2007092315A3
WO2007092315A3 PCT/US2007/002907 US2007002907W WO2007092315A3 WO 2007092315 A3 WO2007092315 A3 WO 2007092315A3 US 2007002907 W US2007002907 W US 2007002907W WO 2007092315 A3 WO2007092315 A3 WO 2007092315A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunostimulation
cpg oligonucleotide
virus complexes
virus
methods
Prior art date
Application number
PCT/US2007/002907
Other languages
French (fr)
Other versions
WO2007092315A2 (en
Inventor
Eyal Raz
Sandip Datta
Kenji Takabayashi
Jeffrey D Lifson
Original Assignee
Univ California
Us Gov Health & Human Serv
Eyal Raz
Sandip Datta
Kenji Takabayashi
Jeffrey D Lifson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Us Gov Health & Human Serv, Eyal Raz, Sandip Datta, Kenji Takabayashi, Jeffrey D Lifson filed Critical Univ California
Publication of WO2007092315A2 publication Critical patent/WO2007092315A2/en
Publication of WO2007092315A3 publication Critical patent/WO2007092315A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025—Nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Immunogenic compositions including an inactivated virus, such as an inactivated retrovirus and at least one phosphorothioate modified oligonucleotide (PS-ODN) are provided. Methods for the production of such immunogenic compositions are disclosed, as are methods for their use to elicit an immune response.
PCT/US2007/002907 2006-02-03 2007-02-01 Immunostimulation by cpg oligonucleotide-virus complexes WO2007092315A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76522506P 2006-02-03 2006-02-03
US60/765,225 2006-02-03

Publications (2)

Publication Number Publication Date
WO2007092315A2 WO2007092315A2 (en) 2007-08-16
WO2007092315A3 true WO2007092315A3 (en) 2007-11-01

Family

ID=38345682

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/002907 WO2007092315A2 (en) 2006-02-03 2007-02-01 Immunostimulation by cpg oligonucleotide-virus complexes

Country Status (1)

Country Link
WO (1) WO2007092315A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012211043B2 (en) 2011-01-27 2017-04-06 Gamma Vaccines Pty Limited Combination vaccines
CN113521274A (en) * 2020-04-17 2021-10-22 北京科兴中维生物技术有限公司 COVID-19 inactivated vaccine composition and application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610661B1 (en) * 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US20040136962A1 (en) * 1998-11-30 2004-07-15 Renner Wolfgang A. Ordered molecular presetation of antigens, method of preparation and use
US20050196383A1 (en) * 2003-11-05 2005-09-08 Zurbriggen Rinaldo E. Compositions and methods for the potentiation of immune responses against target antigens
US20050245477A1 (en) * 1994-07-15 2005-11-03 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US20050266024A1 (en) * 2002-03-19 2005-12-01 Powdermed Limited Adjuvant

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050245477A1 (en) * 1994-07-15 2005-11-03 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6610661B1 (en) * 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US20040136962A1 (en) * 1998-11-30 2004-07-15 Renner Wolfgang A. Ordered molecular presetation of antigens, method of preparation and use
US20050266024A1 (en) * 2002-03-19 2005-12-01 Powdermed Limited Adjuvant
US20050196383A1 (en) * 2003-11-05 2005-09-08 Zurbriggen Rinaldo E. Compositions and methods for the potentiation of immune responses against target antigens

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MCMICHAEL ET AL.: "HIV vaccines 1983-2003", NAT. MED., vol. 9, no. 7, July 2003 (2003-07-01), pages 874 - 880 *
MOSS ET AL.: "Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp 120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA", J. HUM. VIROL., vol. 4, no. 39, 2001 *
ROSSIO ET AL.: "Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins", J. VIROL., vol. 72, 1998, pages 799 - 800 *
TIGHE ET AL.: "Conjugation of protein to immunostimulation DNA Results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity", EUR. J. IMMUNOL.INT., vol. 30, no. 1939, 2000 *

Also Published As

Publication number Publication date
WO2007092315A2 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
WO2009014887A3 (en) Stabilized immune modulatory rna (simra) compounds
WO2006091915A3 (en) Immunostimulatory oligonucleotides
WO2007117686A3 (en) Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
MX2010008779A (en) Storage-stable product systems for premix formulations.
WO2007095316A3 (en) Compositions and methods for oligonucleotide formulations
MY160201A (en) Immunostimulatory oligonucleotides
IN2014DN08830A (en)
WO2009133573A3 (en) A homeopathic formulation
WO2009010877A3 (en) Conjugate purification
WO2011139911A3 (en) Lipid formulated single stranded rna
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
NZ588884A (en) Cross-linkers and their uses
WO2007088423A3 (en) Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone
MY165643A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
MX343111B (en) Immunogenic compositions of staphylococcus aureus antigens.
WO2009080806A3 (en) Modified influenza virus
MX344972B (en) Immunostimulatory oligonucleotides.
AU2008309264A8 (en) Immune stimulatory oligonucleotide analogs containing modified sugar moieties
WO2007144779A3 (en) Compositions comprising porphyra and methods of making and using thereof
WO2011160052A3 (en) Methods and compositions for sequence specific rna endonucleases
WO2010110599A3 (en) Novel αlpha-neoagarobiose hydrolase, and method for obtaining a monosaccharide using same
WO2009129387A3 (en) Cationic lipids and uses thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07763276

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07763276

Country of ref document: EP

Kind code of ref document: A2